C4 Therapeutics (CCCC) Insider Owen Hughes Buys 62,000 Shares
Insider Owen Hughes picked up 62,000 shares of C4 Therapeutics, Inc. on June 24, 2026, joining a broader wave of leadership purchases.
Reviewed by automated data checks against the source filing. How we make and check alerts
Owen Hughes bought 62,000 shares of C4 Therapeutics, Inc. ($CCCC) on June 24, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $CCCC is up 2.1% after 1 week, down 20.0% after 1 month and down 34.8% to date (from the $4.25 close on Jun 24, 2026).
CCCC
C4 Therapeutics, Inc.
Key Points
- Insider Owen Hughes acquired 62,000 shares of C4 Therapeutics, Inc. on June 24, 2026.
- The biotechnology company trades near $4.40 per share, moving well above its 52-week low of $1.69 and close to its 52-week high of $5.17.
- JP Morgan recently initiated coverage on the firm with an overweight rating and a $10.00 price target ahead of upcoming November earnings.
Get $CCCC trade alerts by text
We text you when insiders, Congress or big funds trade $CCCC. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated C4 Therapeutics, Inc. alert may contain errors. Disclosures
Insider Buying and Selling at C4 Therapeutics, Inc.
C4 Therapeutics, Inc. (NasdaqGS: CCCC) saw insider Owen Hughes acquire 62,000 shares on June 24, 2026. This transaction formed part of a coordinated round of acquisitions executed by company leaders on the exact same date. Other members of the team, including Ronald Cooper, Utpal Koppikar, Donna Roy Grogan, Stephen Fawell, and Laura Bessen, also each picked up 62,000 shares on June 24, 2026. These coordinated purchases took place without reported dollar values on the transaction forms.
Stock Performance and Recent Range
Shares of C4 Therapeutics recently traded at $4.40 apiece, sitting near the higher end of the firm's 52-week trading bounds. The equity has moved between a low of $1.69 and a high of $5.17 over the past year. This pricing places the stock comfortably above both its 50-day moving average of $3.74 and its 200-day moving average of $3.09. The clinical-stage biotechnology firm currently holds a market capitalization of roughly $405.98 million.
Analysts Set New Price Targets
External financial institutions follow the clinical pipeline closely. On October 9, 2026, JP Morgan started tracking the stock by issuing an overweight rating alongside a $10.00 price target. Across the wider professional community, six analysts provide regular opinions on the enterprise. These experts maintain a consensus target mean price of $13.33, with individual price targets stretching from a low of $7.00 up to a high of $30.00.
Pipeline and Business Focus
Headquartered in Watertown, Massachusetts, C4 Therapeutics develops novel therapeutic candidates designed to degrade disease-causing proteins. Its clinical pipeline features compounds targeting multiple myeloma and solid tumors, alongside early research programs directed at inflammation and neurodegeneration. The enterprise partners with major pharmaceutical players like Roche Holding AG to advance its degrader-antibody conjugates.
Looking Ahead to November Earnings
Market participants continue tracking leadership sentiment and upcoming financial reports. The company is scheduled to deliver its next quarterly update on November 5, 2026. Observers will monitor future regulatory filings to see if executives expand their holdings further as clinical trials progress.
Related Filing Alerts
Source: Owen Hughes's Form 4 filing on $CCCC (Jun 24, 2026). Find the original filing: CCCC Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts